Todd Freudenberger, MD
Pulmonary Disease · Bellevue, WANPI 1932122876
Payments from drug & device makers
Across 34 payments — averaging $127.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$3K
- Johnson & Johnson$1K
- Sanofi-aventis U.S. LLC$97
- Abiomed$55
- United Therapeutics Corporation$45
- ERBE USA Inc$18
- plus $17 from 1 others
What the payments were for
- Travel & lodging$3,24075%
- Food & beverage$93422%
- Education$1594%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 13 | $3,031 |
| Johnson & Johnson | 14 | $1,069 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Abiomed | 2 | $55 |
| United Therapeutics Corporation | 2 | $45 |
| ERBE USA Inc | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MONARCH$2,836
- Monarch Platform$795
How this compares
$4,332 in reported general payments places this provider in the 75th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 61 | $758,522 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 131 | $121,924 |
| Breo ElliptaFluticasone/Vilanterol | 158 | $103,476 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $71,171 |
| Spiriva HandihalerTiotropium Bromide | 47 | $44,082 |
| Spiriva RespimatTiotropium Bromide | 46 | $38,352 |
| XolairOmalizumab | 13 | $33,584 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $31,970 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $24,459 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $16,680 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 73 | $11,744 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $11,725 |
| Pirfenidone | 12 | $9,165 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $8,945 |
| Qvar RedihalerBeclomethasone Dipropionate | 22 | $7,978 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Bellevue
- Radha AgrawalBellevue$8K
- Peter ChenSeattle$2.7M
- Tomasz ZiedalskiEverett$1.6M
- William ParkRenton$1.2M
- Patrick MeehanTacoma$1.1M
- Pradeep SinghSeattle$1.1M
- Moira AitkenSeattle$700K
- Christopher GossSeattle$487K
- Anthony GerbinoSeattle$448K
- Lawrence HoSeattle$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.